J.Jpn. Surg. Soc.. 79(9): 1084-1088, 1978
Report on the annual meeting
SENSITIVITY TEST OF ANTI-CANCER AGENTS AND EVOLUTION OF COMBINATION CANCER CHEMOTHERAPY
|
The Second Department of Surgery, Osaka University Medical School, Osaka, Japan Hiromu Higashi, Daisuke Amakata, Masao Uematsu, Masahiro Kaji, Shin-ichiro Takai, Goro Kosaki |
For the past ten years time, clinical choice of anti-cancer agents in our clinic was reliable to the INAS (Inhibition of Nucleic Acid Synthesis) method we developed.
Briefly, tumor slices obtained from biopsy or surgery are trimmed to 500 μ thickness and incubated with anti-cancer agent for 4 hours, followed by another I hour incubation with DNA precursor, 14C-formate or 3H-TdR. Sensitivity of tumor cells to anti-cancer agent is estimated in respect to inhibition ratio of DNA synthesis.
As incorporation of 14C-formate to DNA is via de novo synthesis pathway while 3H-thymidine via alvage pahtway, features of DNA synthesis of tumor cells will thus be clarified. When the tumor is found to be requiring both pathways of DNA synthesis, the combination of 5FU and bleomycin is recommended, since the former is an inhibitor of de novo pathway while the latter is a salvage inhibitor. Significant effectiveness of this combination chemothrapy to several cancer patients was good encouragement.
Furthermore, combination chemotherapy in respect to schedule dependency between alkylating agents (HN2-O or ACNU) and 5FU, between methotrexate and adriamycin respectively showed significant reinforcement of effectiveness. These findings may be of another encouragement for further effective combination chemotherapy to cancer patients.
To read the PDF file you will need Adobe Reader installed on your computer.